(PharmaNewsWire.Com, January 31, 2020 ) The global apheresis market was valued at USD 1.42 Billion in 2016. This market is expected to grow at a CAGR of 7.7% during the forecast period (2016–2021) to reach USD 2.06 Billion by 2021. The base year considered for the study is 2015 and the forecast for the market size is provided for the period between 2016 and 2021.
Some of the key factors driving the growth of the market include rising prevalence of diseases and growing number of trauma and injury cases, increasing demand for source plasma from biopharmaceutical companies, and the presence of a favorable reimbursement scenario for apheresis. Untapped emerging regions showcase new growth opportunities for this market. However, the growth of the market is restrained by the lack of awareness about apheresis and the high cost of these procedures.
“The therapeutic plasma exchange segment accounted for the largest share of the market”
On the basis of procedure, the market is segmented into automated/donor apheresis and therapeutic apheresis. Therapeutic apheresis is further segmented into therapeutic plasma exchange (TPE), therapeutic cytapheresis, photopheresis, and extracorporeal immunoadsorption (ECI). The therapeutic plasma exchange segment accounted for the largest market share in 2022. The large share of this segment is attributed to the increasing prevalence and incidence of various blood disorders such as sickle-cell anemia and leukemia.
The photopheresis segment is expected to register the highest CAGR during the forecast period due to the increasing demand for photopheresis in organ transplant rejection treatment.
“The disposables segment is expected to grow at the highest CAGR during the forecast period.”
Based on product, the market is segmented into devices and disposables. The disposables segment accounted for the largest share and will be the fastest growing market during the forecast period. This is attributed to the increasing demand for disposables and rising preference for apheresis blood collection.
“The plasmapheresis segment to dominate the apheresis market”
Based on application, the market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, and other applications. The plasmapheresis segment accounted for the largest share of the market. Growth in the plasmapheresis segment can be attributed to the increasing use of plasma fractionation products in the treatment of various diseases and the growing demand for plasma and its components from pharmaceutical and biopharmaceutical companies.
“The centrifugation segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of technology, the market is segmented into centrifugation and membrane separation. The centrifugation segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the increasing use of centrifugation apheresis devices, especially by blood banks. One of the major advantages of centrifugation technology is that it is used for the apheresis of any blood component. However, the time required for setting up a centrifugal interface is higher than that of the membrane-based device.
In this report, the global market has been studied at the regional and country levels. In 2015, North America represented the largest regional market, followed by Europe. While North America will continue to dominate the market during the forecast period, the Asia-Pacific region is expected to register the highest growth. The growth of this regional segment is driven by the improving healthcare infrastructure, significant economic development in emerging markets, and rising focus of key market players in this region.
Some of the key players in this market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), Cerus Corporation (U.S.), B. Braun Melsungen AG (Germany), HemaCare Corporation (U.S.), Kaneka Corporation (Japan), and Nikkiso Co., Ltd. (Japan). These leading players primarily focused on product launches, acquisitions, agreements, collaborations, partnerships, and expansions to help growth in the market.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
